Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been given an average rating of “Moderate Buy” by the seventeen ratings firms that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $55.06.

KYMR has been the topic of several research reports. Oppenheimer upped their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Friday, September 27th. BMO Capital Markets initiated coverage on Kymera Therapeutics in a research note on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective on the stock. UBS Group cut their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Morgan Stanley upped their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. Finally, Stephens restated an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $44.13 on Thursday. Kymera Therapeutics has a one year low of $29.24 and a one year high of $53.27. The business’s 50-day simple moving average is $42.71 and its 200 day simple moving average is $44.65. The stock has a market cap of $2.86 billion, a price-to-earnings ratio of -18.86 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. During the same quarter in the previous year, the firm posted ($0.90) earnings per share. The company’s revenue was down 20.9% compared to the same quarter last year. On average, equities research analysts predict that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Buying and Selling

In related news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the transaction, the insider now directly owns 54,826 shares of the company’s stock, valued at $2,288,985.50. This represents a 5.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its position in Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after purchasing an additional 270 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after purchasing an additional 504 shares during the period. Harbor Capital Advisors Inc. lifted its position in Kymera Therapeutics by 1.7% in the fourth quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock worth $1,649,000 after purchasing an additional 684 shares during the period. KBC Group NV lifted its position in Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Kymera Therapeutics by 8.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock worth $534,000 after purchasing an additional 915 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.